BioMarin Pharmaceutical Inc. (BMRN)
Price:
58.58 USD
( + 0.51 USD)
Your position:
0 USD
ACTION PANEL
ABOUT
Check the
KEY TAKEAWAYS
ASK OUR AI ABOUT THE COMPANY (REGISTER FOR EARLY ACCESS)
(REGISTER FOR EARLY ACCESS) CHOOSE A PROMPT ABOVE TO ASK OUR AI ABOUT THE SPECIFIC INFORMATION
SIMILAR COMPANIES STI SCORE
Similar STI Score
Incyte Corporation
VALUE SCORE:
10
2nd position
Genmab A/S
VALUE SCORE:
11
The best
Agios Pharmaceuticals, Inc.
VALUE SCORE:
12
FUNDAMENTALS
FUNDAMENTALS
FUNDAMENTALS
FUNDAMENTALS PER SHARE
TECHNICAL
DIVIDEND
SIMILAR COMPANIES
DESCRIPTION
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. The company's commercial products also comprise Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme, which is delivered through subcutaneous injection to reduce blood Phe concentrations; Brineura, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; Voxzogo, a once daily injection analog of c-type natriuretic peptide for the treatment of achondroplasia; and Aldurazyme, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase. In addition, it develops valoctocogene roxaparvovec, an adeno associated virus vector, which is in Phase III clinical trial for the treatment of patients with severe hemophilia A; BMN 307, an AAV5 mediated gene therapy, which is in Phase 1/2 clinical trial to normalize blood Phe concentration levels in patients with PKU; and BMN 255 that is in Phase 1/2 clinical trial for treating primary hyperoxaluria. The company serves specialty pharmacies, hospitals, and non-U.S. government agencies, as well as distributors and pharmaceutical wholesalers in the United States, Europe, Latin America, and internationally. BioMarin Pharmaceutical Inc. has license and collaboration agreements with Sarepta Therapeutics, Ares Trading S.A., Catalyst Pharmaceutical Partners, Inc., and Asubio Pharma Co., Ltd. The company was incorporated in 1996 and is headquartered in San Rafael, California.
NEWS
BioMarin Pharmaceutical (BMRN) is a Top-Ranked Momentum Stock: Should You Buy?
zacks.com
2025-08-18 10:50:25Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Why BioMarin Pharmaceutical (BMRN) is a Top Value Stock for the Long-Term
zacks.com
2025-08-13 10:41:33Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Why BioMarin Pharmaceutical (BMRN) is a Top Growth Stock for the Long-Term
zacks.com
2025-08-12 10:46:13Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
BioMarin: Acquisition Of Inozyme Brings Forth Late-Stage ERT BMN 401
seekingalpha.com
2025-08-05 16:20:52BioMarin's revenue growth is strong, with Q2 2025 revenues up 16% year-over-year and full-year guidance raised to $3.125–$3.2 billion. The Inozyme acquisition brings late-stage BMN 401 for ENPP1 deficiency, with pivotal phase 3 data expected in 1H 2026 and potential first-mover advantage. Voxzogo and Palynziq continue to drive growth, with label expansions and new pipeline candidates like BMN 333 poised to further bolster its pipeline.
BioMarin Discontinues Preclinical Drug Candidate, Advances BMN 333 Toward 2030
benzinga.com
2025-08-05 13:11:46On Tuesday, Biomarin Pharmaceutical Inc. BMRN reported second-quarter adjusted earnings of $1.44, up 50% year over year, beating the consensus of 85 cents and sales of $825.41 million, up 16%, beating the consensus of $760.39 million.
BioMarin Beats on Q2 Earnings & Sales, Stock Gains on Raised '25 View
zacks.com
2025-08-05 11:21:12BMRN's Q2 earnings surge 50% on strong Voxzogo and enzyme therapy sales, prompting a raised 2025 revenue and EPS outlook.
BioMarin Pharmaceutical Inc. (BMRN) Q2 2025 Earnings Call Transcript
seekingalpha.com
2025-08-04 23:04:19BioMarin Pharmaceutical Inc. (NASDAQ:BMRN ) Q2 2025 Earnings Conference Call August 4, 2025 4:30 PM ET Company Participants Alexander Hardy - President, CEO & Director Brian R. Mueller - Executive VP of Finance & CFO Cristin Hubbard - Executive VP & Chief Commercial Officer Gregory Friberg - Executive VP and Chief Research & Development Officer Traci McCarty - Group Vice President Conference Call Participants Akash Tewari - Jefferies LLC, Research Division Alexandria Janet Hammond - Wolfe Research, LLC Allison Marie Bratzel - Piper Sandler & Co., Research Division Cory William Kasimov - Evercore ISI Institutional Equities, Research Division Ellen Horste - TD Cowen, Research Division Huidong Wang - Barclays Bank PLC, Research Division Jasmine Alexandra Fels - UBS Investment Bank, Research Division Jason Matthew Gerberry - BofA Securities, Research Division Konstantinos Biliouris - BMO Capital Markets Equity Research Olivia Simone Brayer - Cantor Fitzgerald & Co., Research Division Paul Andrew Matteis - Stifel, Nicolaus & Company, Incorporated, Research Division Sean M.
BioMarin (BMRN) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates
zacks.com
2025-08-04 19:00:36Although the revenue and EPS for BioMarin (BMRN) give a sense of how its business performed in the quarter ended June 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
BioMarin Pharmaceutical (BMRN) Q2 Earnings and Revenues Surpass Estimates
zacks.com
2025-08-04 18:21:10BioMarin Pharmaceutical (BMRN) came out with quarterly earnings of $1.44 per share, beating the Zacks Consensus Estimate of $1.03 per share. This compares to earnings of $0.96 per share a year ago.
BioMarin (BMRN) Q2 Revenue Jumps 16%
fool.com
2025-08-04 18:07:15BioMarin (BMRN) Q2 Revenue Jumps 16%
BioMarin Reports Strong Second Quarter 2025 Results and Raises Full-year Guidance¹ for Total Revenues, Non-GAAP Operating Margin, and Non-GAAP Diluted EPS
prnewswire.com
2025-08-04 16:02:00Second Quarter 2025 Total Revenues of $825 million (+16% Y/Y and +17% at Constant Currency Y/Y) Second Quarter 2025 GAAP Diluted Earnings Per Share (EPS) of $1.23 (+124% Y/Y) Second Quarter 2025 Non-GAAP Diluted EPS of $1.44 (+50% Y/Y) BioMarin Completes Acquisition of Inozyme in July 2025; Pivotal Data from Lead Indication Expected 1H'26 BMN 333 Exceeds Targeted Exposures of Free C-type Natriuretic Peptide (CNP) in Healthy Volunteer Study; Pivotal Phase 2/3 Study with BMN 333 in Pediatric Achondroplasia Planned to Begin 1H'26 Conference Call and Webcast Scheduled Today at 4:30 p.m. ET SAN RAFAEL, Calif.
BioMarin Announces Appointment of Ian T. Clark to Board of Directors
prnewswire.com
2025-08-01 09:00:00SAN RAFAEL, Calif. , Aug. 1, 2025 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) announced that the company has appointed Ian T.
BioMarin Pharmaceutical (BMRN) Reports Next Week: Wall Street Expects Earnings Growth
zacks.com
2025-07-28 11:06:53BioMarin (BMRN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
BioMarin to Host Second Quarter 2025 Financial Results Conference Call and Webcast on Monday, August 4, 2025, at 4:30pm ET
prnewswire.com
2025-07-22 09:00:00SAN RAFAEL, Calif. , July 22, 2025 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Alexander Hardy, President and Chief Executive Officer of BioMarin, will host a conference call and webcast on Monday, August 4, 2025, at 4:30 p.m.
Looking for a Growth Stock? 3 Reasons Why BioMarin (BMRN) is a Solid Choice
zacks.com
2025-07-16 13:46:06BioMarin (BMRN) possesses solid growth attributes, which could help it handily outperform the market.
Wall Street Analysts Think BioMarin (BMRN) Could Surge 70.77%: Read This Before Placing a Bet
zacks.com
2025-07-16 10:56:07The consensus price target hints at a 70.8% upside potential for BioMarin (BMRN). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
No data to display
BioMarin Pharmaceutical (BMRN) is a Top-Ranked Momentum Stock: Should You Buy?
zacks.com
2025-08-18 10:50:25Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Why BioMarin Pharmaceutical (BMRN) is a Top Value Stock for the Long-Term
zacks.com
2025-08-13 10:41:33Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Why BioMarin Pharmaceutical (BMRN) is a Top Growth Stock for the Long-Term
zacks.com
2025-08-12 10:46:13Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
BioMarin: Acquisition Of Inozyme Brings Forth Late-Stage ERT BMN 401
seekingalpha.com
2025-08-05 16:20:52BioMarin's revenue growth is strong, with Q2 2025 revenues up 16% year-over-year and full-year guidance raised to $3.125–$3.2 billion. The Inozyme acquisition brings late-stage BMN 401 for ENPP1 deficiency, with pivotal phase 3 data expected in 1H 2026 and potential first-mover advantage. Voxzogo and Palynziq continue to drive growth, with label expansions and new pipeline candidates like BMN 333 poised to further bolster its pipeline.
BioMarin Discontinues Preclinical Drug Candidate, Advances BMN 333 Toward 2030
benzinga.com
2025-08-05 13:11:46On Tuesday, Biomarin Pharmaceutical Inc. BMRN reported second-quarter adjusted earnings of $1.44, up 50% year over year, beating the consensus of 85 cents and sales of $825.41 million, up 16%, beating the consensus of $760.39 million.
BioMarin Beats on Q2 Earnings & Sales, Stock Gains on Raised '25 View
zacks.com
2025-08-05 11:21:12BMRN's Q2 earnings surge 50% on strong Voxzogo and enzyme therapy sales, prompting a raised 2025 revenue and EPS outlook.
BioMarin Pharmaceutical Inc. (BMRN) Q2 2025 Earnings Call Transcript
seekingalpha.com
2025-08-04 23:04:19BioMarin Pharmaceutical Inc. (NASDAQ:BMRN ) Q2 2025 Earnings Conference Call August 4, 2025 4:30 PM ET Company Participants Alexander Hardy - President, CEO & Director Brian R. Mueller - Executive VP of Finance & CFO Cristin Hubbard - Executive VP & Chief Commercial Officer Gregory Friberg - Executive VP and Chief Research & Development Officer Traci McCarty - Group Vice President Conference Call Participants Akash Tewari - Jefferies LLC, Research Division Alexandria Janet Hammond - Wolfe Research, LLC Allison Marie Bratzel - Piper Sandler & Co., Research Division Cory William Kasimov - Evercore ISI Institutional Equities, Research Division Ellen Horste - TD Cowen, Research Division Huidong Wang - Barclays Bank PLC, Research Division Jasmine Alexandra Fels - UBS Investment Bank, Research Division Jason Matthew Gerberry - BofA Securities, Research Division Konstantinos Biliouris - BMO Capital Markets Equity Research Olivia Simone Brayer - Cantor Fitzgerald & Co., Research Division Paul Andrew Matteis - Stifel, Nicolaus & Company, Incorporated, Research Division Sean M.
BioMarin (BMRN) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates
zacks.com
2025-08-04 19:00:36Although the revenue and EPS for BioMarin (BMRN) give a sense of how its business performed in the quarter ended June 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
BioMarin Pharmaceutical (BMRN) Q2 Earnings and Revenues Surpass Estimates
zacks.com
2025-08-04 18:21:10BioMarin Pharmaceutical (BMRN) came out with quarterly earnings of $1.44 per share, beating the Zacks Consensus Estimate of $1.03 per share. This compares to earnings of $0.96 per share a year ago.
BioMarin (BMRN) Q2 Revenue Jumps 16%
fool.com
2025-08-04 18:07:15BioMarin (BMRN) Q2 Revenue Jumps 16%
BioMarin Reports Strong Second Quarter 2025 Results and Raises Full-year Guidance¹ for Total Revenues, Non-GAAP Operating Margin, and Non-GAAP Diluted EPS
prnewswire.com
2025-08-04 16:02:00Second Quarter 2025 Total Revenues of $825 million (+16% Y/Y and +17% at Constant Currency Y/Y) Second Quarter 2025 GAAP Diluted Earnings Per Share (EPS) of $1.23 (+124% Y/Y) Second Quarter 2025 Non-GAAP Diluted EPS of $1.44 (+50% Y/Y) BioMarin Completes Acquisition of Inozyme in July 2025; Pivotal Data from Lead Indication Expected 1H'26 BMN 333 Exceeds Targeted Exposures of Free C-type Natriuretic Peptide (CNP) in Healthy Volunteer Study; Pivotal Phase 2/3 Study with BMN 333 in Pediatric Achondroplasia Planned to Begin 1H'26 Conference Call and Webcast Scheduled Today at 4:30 p.m. ET SAN RAFAEL, Calif.
BioMarin Announces Appointment of Ian T. Clark to Board of Directors
prnewswire.com
2025-08-01 09:00:00SAN RAFAEL, Calif. , Aug. 1, 2025 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) announced that the company has appointed Ian T.
BioMarin Pharmaceutical (BMRN) Reports Next Week: Wall Street Expects Earnings Growth
zacks.com
2025-07-28 11:06:53BioMarin (BMRN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
BioMarin to Host Second Quarter 2025 Financial Results Conference Call and Webcast on Monday, August 4, 2025, at 4:30pm ET
prnewswire.com
2025-07-22 09:00:00SAN RAFAEL, Calif. , July 22, 2025 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Alexander Hardy, President and Chief Executive Officer of BioMarin, will host a conference call and webcast on Monday, August 4, 2025, at 4:30 p.m.
Looking for a Growth Stock? 3 Reasons Why BioMarin (BMRN) is a Solid Choice
zacks.com
2025-07-16 13:46:06BioMarin (BMRN) possesses solid growth attributes, which could help it handily outperform the market.
Wall Street Analysts Think BioMarin (BMRN) Could Surge 70.77%: Read This Before Placing a Bet
zacks.com
2025-07-16 10:56:07The consensus price target hints at a 70.8% upside potential for BioMarin (BMRN). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.